Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Industry News

Positive Five-Year Data Published for MiStent in EuroIntervention

January 12, 2018

News Industry News

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

August 15, 2017

News Industry News

LivaNova PLC Announces the First Patient Enrolled in the PERSIST-AVR Trial

April 04, 2016

News Industry News

China Interventional Cardiovascular Device Industry Report, 2014-2017

May 27, 2015

News Industry News

Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014

September 16, 2014

News Industry News

Elixir Medical Announces Schedule of Programs for TCT 2014

September 08, 2014

News Industry News

Elixir Medical Announces Outstanding Long-term Clinical Results at EuroPCR for World’s Broadest Portfolio of Three CE Mark-approved Novolimus Eluting Coronary Intervention Systems

May 23, 2014

News Industry News

Micell Technologies Announces Clinical Data from MiStent SES Studies Will Be Presented at EuroPCR 2014

May 15, 2014

News Industry News

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

October 31, 2013

News Industry News

MiStent SES Shown to be Unique in Clinical Setting

October 29, 2013

News Industry News

Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013

October 17, 2013

News Industry News

Micell Technologies Receives CE Mark Approval for MiStent SES

June 12, 2013

News Industry News

Elixir Medical Corporation to Announce 6-month Results of the DESolve Fully Bioresorbable Coronary Scaffold System Pivotal Trial at Late Breaking Trial Session of EuroPCR

May 01, 2013

News Industry News

Elixir Medical Corporation Announces Outstanding Three-Year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System

October 24, 2012

News Industry News

Elixir Medical Corporation Announces Outstanding Three-year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System(2)

October 24, 2012

News Industry News

Micell Technologies Announces Positive Data from Clinical Studies of MiStent SES

October 23, 2012

News Industry News

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results from the EXCELLA BD Randomized Clinical Trial

November 08, 2011

News Industry News

Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System

November 07, 2011

News Industry News

Medtronic’s Unmatched Portfolio of Cardiovascular Devices Features Prominently on Program for TCT 2011

November 04, 2011

News Industry News

Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent® Drug-Eluting Coronary Stent

July 26, 2011

Advertisement

Positive Five-Year Data Published for MiStent in EuroIntervention

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

LivaNova PLC Announces the First Patient Enrolled in the PERSIST-AVR Trial

China Interventional Cardiovascular Device Industry Report, 2014-2017

Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014

Elixir Medical Announces Schedule of Programs for TCT 2014

Elixir Medical Announces Outstanding Long-term Clinical Results at EuroPCR for World’s Broadest Portfolio of Three CE Mark-approved Novolimus Eluting Coronary Intervention Systems

Micell Technologies Announces Clinical Data from MiStent SES Studies Will Be Presented at EuroPCR 2014

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

MiStent SES Shown to be Unique in Clinical Setting

Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013

Micell Technologies Receives CE Mark Approval for MiStent SES

Elixir Medical Corporation to Announce 6-month Results of the DESolve Fully Bioresorbable Coronary Scaffold System Pivotal Trial at Late Breaking Trial Session of EuroPCR

Elixir Medical Corporation Announces Outstanding Three-Year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System

Elixir Medical Corporation Announces Outstanding Three-year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System(2)

Micell Technologies Announces Positive Data from Clinical Studies of MiStent SES

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results from the EXCELLA BD Randomized Clinical Trial

Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System

Medtronic’s Unmatched Portfolio of Cardiovascular Devices Features Prominently on Program for TCT 2011

Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent® Drug-Eluting Coronary Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content